Alzheimer's biotech Alzheon nets $50M Se­ries D; Evelo puts PhI atopic der­mati­tis pro­gram on hold

A Fram­ing­ham, MA-based biotech has some new cash to play with.

Alzheon an­nounced Thurs­day morn­ing it has com­plet­ed a $50 mil­lion Se­ries D round aimed to ad­vance a Phase III study for its oral Alzheimer’s pro­gram, as well as to help prep the drug’s reg­u­la­to­ry fil­ings. The can­di­date, dubbed ALZ-801, is an oral tablet be­ing eval­u­at­ed for pa­tients with ear­ly-stage Alzheimer’s dis­ease.

“[The] Se­ries D fi­nanc­ing and re­cent val­i­dat­ing da­ta will ac­cel­er­ate de­vel­op­ment of ALZ-801 to po­ten­tial­ly be­come the first oral agent that can slow or even stop and pre­vent Alzheimer’s pathol­o­gy in all pa­tients and healthy in­di­vid­u­als at risk for the dis­ease,” CEO Mar­tin To­lar said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER